Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study.
Lexington, Massachusetts-based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated with the company’s Revita system for resurfacing the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes.
Get the full story at our sister site, Drug Delivery Business News.